Research into the glomerular podocyte - Is it relevant to diabetic nephropathy?

Diabetic Medicine

Volumn 23, Issue 7, 2006, Pages 715-719

  White, K E ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Glomerular filtration; Glomerulopathy; Proteinuria

Indexed keywords

ALBUMIN; ALPHA3 INTEGRIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3B RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PODOCALYXIN; PROTEIN;

CELL DAMAGE; CELL STRUCTURE; CYTOPLASM; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE MUTATION; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PODOCYTE; PROTEINURIA; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; PODOCYTES; PROTEINURIA; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM;

EID: 33748542944     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01790.x     Document Type: Review

References (39)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
2. Marshall SM. Recent advances in diabetic nephropathy. Clin Med 2004; 4: 277-282.
3. Diabetes Control and Complications Trial. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
5. Osterby R, Parving HH, Hommel E, Jorgensen HE, Lokkegaard H. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes 1990; 39: 1057-1063.
6. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000; 11: 1667-1673.
7. Osterby R, Parving HH, Nyberg G, Hommel E, Jorgensen HE, Lokkegaard H et al. A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy. Diabetologia 1988; 31: 265-270.
8. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-2307.
9. Bjorn SF, Bangstad HJ, Hanssen KF, Nyberg G, Walker JD, Viberti GC et al. Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 1995; 38: 1197-1204.
10. Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestila M et al. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004; 15: 2611-2618.
11. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440.
12. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30-39.
13. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P et al. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001; 12: 413-422.
14. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R et al. Effects of high glucose and TGF-β 1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913.
15. Kanellis J, Levidiotis V, Khong T, Cox AJ, Stacker SA, Gilbert RE et al. A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol 2004; 96: P26-36.
16. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
17. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-2113.
18. Lemley KV, Abdullah I, Myers BD, Meyer TW, Blouch K, Smith WE et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000; 58: 1228-1237.
19. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
20. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083-3089.
21. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
22. Hara M, Yanagihara T, Itoh M, Matsuno M, Kihara I. Immunohistochemical and urinary markers of podocyte injury. Pediatr Nephrol 1998; 12: 43-48.
23. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001; 89: 342-347.
24. White KE, Bilous RW. Estimation of podocyte number: a comparison of methods. Kidney Int 2004; 66: 663-667.
25. Osterby R, Gundersen HJ. Fast accumulation of basement membrane material and the rate of morphological changes in acute experimental diabetic glomerular hypertrophy. Diabetologia 1980; 18: 493-500.
26. Lewko B, Bryl E, Witkowski JM, Latawiec E, Angielski S, Stepinski J. Mechanical stress and glucose concentration modulate glucose transport in cultured rat podocytes. Nephrol Dial Transplant 2005; 20: 306-311.
27. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999; 10: 2440-2445.
28. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45: 1572-1576.
29. Aaltonen P, Luimula P, Astrom E, Palmen T, Gronholm T, Palojoki E et al. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001; 81: 1185-1190.
30. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-2200.
31. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-2071.
32. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of α3β1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67: 2345-2353.
33. Santilli F, Spagnoli A, Mohn A, Tumini S, Verrotti A, Cipollone F et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001; 86: 3871-3876.
34. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000; 20: 373-379.
35. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882.
36. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of antiproteinuric therapies. Nephrol Dial Transplant 2002; 17: 1327-1332.
37. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
38. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000; 11: 477-489.
39. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741.